89bio, Inc. ETNB
Set alert
At close · Oct 30
52-week range unavailable
- YTD
- +89.77%
- 1 year
- +85.73%
- Open
- 14.84
- Prev close
- 14.84
- Mkt cap
- 2.20B
- Vol
- 38.51M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 14.84
- High
- 14.84
- Forward P/E
- -5.17
- Beta
- 1.26
- Short ratio
- 0.74
- Inst. own
- 103.69%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 12.52
- 200-d avg
- 9.87
- 1y target
- 30.38
Key statistics
- Market cap
- 2.20B
- Enterprise value
- 1.68B
- Trailing P/E
- 0.00
- Forward P/E
- -5.17
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.22
- EPS (TTM)
- -3.69
- Beta
- 1.26
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -257.73M
- Total cash
- 561.16M
- Total debt
- 37.62M
- Return on equity
- -86.86%
- Shares outstanding
- 148.49M
- Short % of float
- 6.30%
- 50-day average
- 12.52
- 200-day average
- 9.87
Analyst view
Consensus: buy
- Target (low)
- 14.50
- Target (mean)
- 30.38
- Target (high)
- 55.00
- Strong buy0
- Buy2
- Hold4
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.49667.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 19, 2025 | Raymond James | down | Outperform | Market Perform |
| Sep 19, 2025 | Wolfe Research | down | Outperform | Peer Perform |
| Sep 19, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 25, 2025 | B of A Securities | main | Buy | Buy |
| Aug 8, 2025 | RBC Capital | main | Sector Perform | Sector Perform |
| Mar 14, 2025 | Goldman Sachs | init | — | Neutral |
About 89bio, Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as The company was founded in 2018 and is based in San Francisco, California. As of October 29, 2025, 89bio, Inc. operates as a subsidiary of Roche Holding AG.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- 89bio.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ETNB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| LE-NGUYEN QUOC | Chief Operating Officer | Stock Award(Grant) | Oct 29, 2025 | 0 |
| MANSBACH HARRY H | Officer | Stock Award(Grant) | Jan 30, 2025 | 323,701 |
| MARTINS RYAN | Chief Financial Officer | Conversion of Exercise of derivative security | Oct 21, 2025 | 339,295 |
| MCWHERTER CHARLES A | Director | Purchase | Jan 21, 2025 | 25,000 |
| PALEKAR ROHAN | Chief Executive Officer | Stock Award(Grant) | Jan 30, 2025 | 873,638 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 29, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Janus Henderson Group PLC | 14.02% | 20,788,363 | 308.50M | Jun 29, 2025 |
| RA Capital Management, L.P. | 13.41% | 19,889,683 | 295.16M | Jun 29, 2025 |
| Suvretta Capital Management, LLC | 9.58% | 14,210,000 | 210.88M | Jun 29, 2025 |
| Blackrock Inc. | 7.13% | 10,569,424 | 156.85M | Jun 29, 2025 |
| Deep Track Capital, Lp | 6.41% | 9,500,000 | 140.98M | Jun 29, 2025 |
| Vanguard Group Inc | 5.56% | 8,242,154 | 122.31M | Jun 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.24% | 4,805,776 | 71.32M | Jun 29, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 2.07% | 3,065,984 | 45.50M | Sep 29, 2025 |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 1.97% | 2,923,449 | 43.38M | Jun 29, 2025 |
| SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF | 1.72% | 2,552,389 | 37.88M | Sep 29, 2025 |
| JANUS INVESTMENT FUND-Janus Henderson Triton Fund | 1.58% | 2,345,178 | 34.80M | Jun 29, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.35% | 2,007,886 | 29.80M | Jun 29, 2025 |